The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study.
M. Bitzer
No relevant relationships to disclose
M. Horger
No relevant relationships to disclose
T. M. Ganten
No relevant relationships to disclose
M. P. Ebert
No relevant relationships to disclose
J. T. Siveke
No relevant relationships to disclose
M. A. Woerns
No relevant relationships to disclose
M. M. Dollinger
No relevant relationships to disclose
G. Gerken
No relevant relationships to disclose
M. E. Scheulen
No relevant relationships to disclose
A. Mais
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
R. Jankowsky
Employment or Leadership Position - 4SC
B. Hauns
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
B. Hentsch
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
U. M. Lauer
No relevant relationships to disclose